Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.

ADCY4 inhibits cAMP-induced growth of breast cancer by inactivating FAK/AKT and ERK signaling but is frequently silenced by DNA methylation

Open access
Pan, Guangrui, Huang, Mingquan, Fu, Shaozhi, Wang, Yu, He, Lijia, Wu, Bin, Yang, Jinping, Lin, Sheng, Fan, Yu · 2025 · Scientific Reports

Abstract

Local increases in cyclic adenosine monophosphate (cAMP) caused by specific adenylyl cyclases (ACs) can selectively modulate related proteins. AC-selective drugs have an advantage in side effect control, and the specific AC may finally be considered as a therapeutic target. We show that adenylyl cyclase 4 (ADCY4), which is silenced by DNA methylation and is critical for breast cancer (BC) patient survival, plays essential roles in anti-tumor effects in BC cells. DNA methyltransferase inhibitor and histone deacetylase inhibitor can restore ADCY4 mRNA expression in ADCY4-silenced BC cells. ADCY4 directly affects BC cell proliferation, apoptosis, invasion, and metastasis. Mechanistically, ADCY4 converts ATP to cAMP and activates cAMP/PKA signaling, leading to a decrease in the phosphorylation level of downstream FAK/AKT and ERK signaling and creating a suppression environment for cell survival. Ectopic ADCY4 inhibits BC growth, which is blocked by cAMP inhibition, activating AKT and ERK. The present study provides evidence that human BC relies upon this epigenetic silenced ADCY4-associated ATP-cAMP loop for phosphorylation and activation of FAK/AKT and ERK signaling. Also, ADCY4 increases BC cell chemosensitivity to paclitaxel. The observations demonstrates that ADCY4 is a significant tumor suppressor and that loss of ADCY4 functions by DNA methylation hampers cAMP signaling and triggers FAK/AKT and ERK signaling during breast tumorigenesis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41598-025-06294-1

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 ADCY4 is downregulated in BC and associated with poor prognosis. (A) ADCY4 mRNA expression in primary BC (n = 20) and paired adjacent noncancer tissues (n = 20) by qRT-PCR with β-actin as a control (p = 0.0237, < 0.05). (B) ADCY4 mRNA expression in normal tissues and BC from TCGA datasets using R 3.6.3. package (p = 7.262E-52, < 0.001). (C) ADCY4 mRNA expression in normal tissues (n = 92), adjacent noncancer (n = 104), and BC (n = 1034) from GTEx and TCGA datasets (p < 0.001). (D) The OS rate in the group of high and low ADCY4 expression from TCGA datasets (p = 0.0056, < 0.01). Cutoff value: the median expression level. (E) The difference of OS rate for BC in high and low ADCY4 based on GSE1456 (p = 0.021569, < 0.05). (F) The difference of OS rate for BC in high and low ADCY4 based on GSE3494 (p = 0.017310, < 0.05). (G) Representative IHC staining images of ADCY4 protein expression in adjacent normal breast and BC tissues. The IHC score of ADCY4 in 10 BC specimens (IHC score: 3.10 ± 0.88) was lower than paired 10 adjacent normal breast samples (IHC score: 10.50 ± 2.12) (Mean ± S.D). NC, adjacent normal breast tissues; BrCa, BC tissues. ***p < 0.001.
Fig. 1 ADCY4 is downregulated in BC and associated with poor prognosis. (A) ADCY4 mRNA expression in primary BC (n = 20) and paired adjacent noncancer tissues (n = 20) by qRT-PCR with β-actin as a control (p = 0.0237, < 0.05). (B) ADCY4 mRNA expression in normal tissues and BC from TCGA datasets using R 3.6.3. package (p = 7.262E-52, < 0.001). (C) ADCY4 mRNA expression in normal tissues (n = 92), adjacent noncancer (n = 104), and BC (n = 1034) from GTEx and TCGA datasets (p < 0.001). (D) The OS rate in the group of high and low ADCY4 expression from TCGA datasets (p = 0.0056, < 0.01). Cutoff value: the median expression level. (E) The difference of OS rate for BC in high and low ADCY4 based on GSE1456 (p = 0.021569, < 0.05). (F) The difference of OS rate for BC in high and low ADCY4 based on GSE3494 (p = 0.017310, < 0.05). (G) Representative IHC staining images of ADCY4 protein expression in adjacent normal breast and BC tissues. The IHC score of ADCY4 in 10 BC specimens (IHC score: 3.10 ± 0.88) was lower than paired 10 adjacent normal breast samples (IHC score: 10.50 ± 2.12) (Mean ± S.D). NC, adjacent normal breast tissues; BrCa, BC tissues. ***p < 0.001.CC BY-NC-ND · PubMed Central
Fig. 2 Identification of ADCY4 silenced by promoter methylation in BC. (A) The CpG islands in the LTBP4 nucleotide sequence (EMBOSS-cpgplot). Each red arrows represents a single CpG island. (B) ADCY4 methylation in primary BC tissues (n = 171) and normal tissues (n = 11) measured by MSP. m-, methylated, u-, unmethylated. Gel images showed the representational graphs. (C) The differences in methylation levels of ADCY4 in primary BC (n = 793) and normal tissues (n = 97) from TCGA datasets. (D) The correlation between ADCY4 methylation and expression from TCGA-BRCA datasets was analyzed using cBioPortal online software (n = 1253, r=-0.19, p = 1.35E-11, < 0.001); (E) ADCY4 mRNA expression and methylation status in BC cell lines. m-, methylated, u-, unmethylated. (F) ADCY4 methylation status with 5-aza-2-deoxycytidine (A) and trichostatin A (T) treatments in BC cell lines. m-, methylated, u-, unmethylated. (G) ADCY4 expression with 5-aza-2-deoxycytidine (A) and trichostatin A (T) treatments in BC cell lines by qRT-PCR. **p < 0.01.
Fig. 2 Identification of ADCY4 silenced by promoter methylation in BC. (A) The CpG islands in the LTBP4 nucleotide sequence (EMBOSS-cpgplot). Each red arrows represents a single CpG island. (B) ADCY4 methylation in primary BC tissues (n = 171) and normal tissues (n = 11) measured by MSP. m-, methylated, u-, unmethylated. Gel images showed the representational graphs. (C) The differences in methylation levels of ADCY4 in primary BC (n = 793) and normal tissues (n = 97) from TCGA datasets. (D) The correlation between ADCY4 methylation and expression from TCGA-BRCA datasets was analyzed using cBioPortal online software (n = 1253, r=-0.19, p = 1.35E-11, < 0.001); (E) ADCY4 mRNA expression and methylation status in BC cell lines. m-, methylated, u-, unmethylated. (F) ADCY4 methylation status with 5-aza-2-deoxycytidine (A) and trichostatin A (T) treatments in BC cell lines. m-, methylated, u-, unmethylated. (G) ADCY4 expression with 5-aza-2-deoxycytidine (A) and trichostatin A (T) treatments in BC cell lines by qRT-PCR. **p < 0.01.CC BY-NC-ND · PubMed Central
Fig. 3 ADCY4 suppresses BC in vitro. (A) Ectopic expression of ADCY4 in BC cell lines was measured by RT-qPCR. (B) Cell viabilities evaluated at 24, 48, 72, and 96 h after ectopic expressing ADCY4 in MDA-MB-231 and MCF-7 cells. (C) Representative colony formation of vector- and of ADCY4-expressing BC cells (left panel). Rates are shown as mean ± SD (right panel) from three independent experiments. (D) Cell cycle distribution measured in vector- and ADCY4-expressing BC cells by flow cytometry. Representative distribution plots and histograms of alterations are shown. (E) Percentages of apoptotic cells with ADCY4 ectopic expression were evaluated. Cell apoptosis alterations were revealed by histograms. (F) The cellular invasion abilities of BC cells upon ectopic expression of ADCY4 were measured by transwell assays with matrigel. (G) Cell migration abilities of BC cells evaluated by wound healing assays. Photographs captured at 0, 6, 24 and 48 h. Representative images were photographed following fixation and staining. Scale bars: 50 μm. ***p < 0.001, **p < 0.01, *p < 0.05.
Fig. 3 ADCY4 suppresses BC in vitro. (A) Ectopic expression of ADCY4 in BC cell lines was measured by RT-qPCR. (B) Cell viabilities evaluated at 24, 48, 72, and 96 h after ectopic expressing ADCY4 in MDA-MB-231 and MCF-7 cells. (C) Representative colony formation of vector- and of ADCY4-expressing BC cells (left panel). Rates are shown as mean ± SD (right panel) from three independent experiments. (D) Cell cycle distribution measured in vector- and ADCY4-expressing BC cells by flow cytometry. Representative distribution plots and histograms of alterations are shown. (E) Percentages of apoptotic cells with ADCY4 ectopic expression were evaluated. Cell apoptosis alterations were revealed by histograms. (F) The cellular invasion abilities of BC cells upon ectopic expression of ADCY4 were measured by transwell assays with matrigel. (G) Cell migration abilities of BC cells evaluated by wound healing assays. Photographs captured at 0, 6, 24 and 48 h. Representative images were photographed following fixation and staining. Scale bars: 50 μm. ***p < 0.001, **p < 0.01, *p < 0.05.CC BY-NC-ND · PubMed Central
Fig. 4 ADCY4 suppresses BC in vivo and is critical for cAMP/PKA and its downstream signaling pathways. (A) Representative photos showing tumor growth 30 days after subcutaneously injected MCF-7 cells with ADCY4-overexpression or not. (B) Tumors’ volume was measured on each three days. (C) The weight of vector-group and ADCY4-group tumors were measured respectively (n = 5). (D) Representative images of HE staining (original magnification: 800×), The protein levels of Ki-67 was determined by immunohistochemistry (original magnification: 400×). The histogram shows the intensity of immunostaining. All statistical data were shown as mean ± S.D. (E, F) ADCY4 promotes cAMP generation in MDA-MB-231 and MCF-7 cells. (G) WB analysis for phospho-FAK (Tyr397), FAK, phospho-AKT (Ser473), AKT, phospho-ERK1/2 (Thr202/Tyr204), ERK1/2 with ADCY4 ectopic expression, β-actin was used as a loading control. *p < 0. 05, ***p < 0.001.
Fig. 4 ADCY4 suppresses BC in vivo and is critical for cAMP/PKA and its downstream signaling pathways. (A) Representative photos showing tumor growth 30 days after subcutaneously injected MCF-7 cells with ADCY4-overexpression or not. (B) Tumors’ volume was measured on each three days. (C) The weight of vector-group and ADCY4-group tumors were measured respectively (n = 5). (D) Representative images of HE staining (original magnification: 800×), The protein levels of Ki-67 was determined by immunohistochemistry (original magnification: 400×). The histogram shows the intensity of immunostaining. All statistical data were shown as mean ± S.D. (E, F) ADCY4 promotes cAMP generation in MDA-MB-231 and MCF-7 cells. (G) WB analysis for phospho-FAK (Tyr397), FAK, phospho-AKT (Ser473), AKT, phospho-ERK1/2 (Thr202/Tyr204), ERK1/2 with ADCY4 ectopic expression, β-actin was used as a loading control. *p < 0. 05, ***p < 0.001.CC BY-NC-ND · PubMed Central
Fig. 5 Phosphorylation of AKT and ERK signaling is suppressed by ADCY4 ectopic expression. (A) MDA-MB-231 and MCF-7 cells with ADCY4 ectopic expression or control cells were treated with vehicle (DMSO) or SC79, WB analysis for phospho-AKT (Ser473) and AKT. β-actin was used as a loading control. (B) MDA-MB-231 and MCF-7 cells with ADCY4 ectopic expression or control cells were treated the same as in (A), the cell viabilities were measured by MTT assay at 24, 48, 72, and 96 h. (C) MDA-MB-231 and MCF-7 cells with ADCY4 ectopic expression or control cells were treated the same as in (A), the percentages of apoptotic cells were measured. (D) MDA-MB-231 and MCF-7 cells with ADCY4 ectopic expression or control cells were treated with vehicle (DMSO) or tBHQ, WB analysis for phospho-ERK1/2 (Thr202/Tyr204) and ERK. β-actin was used as a loading control. (E) MDA-MB-231 and MCF-7 cells with ADCY4 ectopic expression or control cells were treated the same as in (D), the cell viabilities were measured by MTT assay at 24, 48, 72, and 96 h. (F) MDA-MB-231 and MCF-7 cells with ADCY4 ectopic expression or control cells were treated the same as in (D), the percentages of apoptotic cells were measured. ***p < 0.001, **p < 0.01, *p < 0.05.
Fig. 5 Phosphorylation of AKT and ERK signaling is suppressed by ADCY4 ectopic expression. (A) MDA-MB-231 and MCF-7 cells with ADCY4 ectopic expression or control cells were treated with vehicle (DMSO) or SC79, WB analysis for phospho-AKT (Ser473) and AKT. β-actin was used as a loading control. (B) MDA-MB-231 and MCF-7 cells with ADCY4 ectopic expression or control cells were treated the same as in (A), the cell viabilities were measured by MTT assay at 24, 48, 72, and 96 h. (C) MDA-MB-231 and MCF-7 cells with ADCY4 ectopic expression or control cells were treated the same as in (A), the percentages of apoptotic cells were measured. (D) MDA-MB-231 and MCF-7 cells with ADCY4 ectopic expression or control cells were treated with vehicle (DMSO) or tBHQ, WB analysis for phospho-ERK1/2 (Thr202/Tyr204) and ERK. β-actin was used as a loading control. (E) MDA-MB-231 and MCF-7 cells with ADCY4 ectopic expression or control cells were treated the same as in (D), the cell viabilities were measured by MTT assay at 24, 48, 72, and 96 h. (F) MDA-MB-231 and MCF-7 cells with ADCY4 ectopic expression or control cells were treated the same as in (D), the percentages of apoptotic cells were measured. ***p < 0.001, **p < 0.01, *p < 0.05.CC BY-NC-ND · PubMed Central
Fig. 6 cAMP plays an important role in ADCY4-regulated signaling pathways. (A) MDA-MB-231 and MCF-7 cells with ADCY4 ectopic expression or control cells were treated with vehicle (DMSO) or SQ22536, cAMP concentration was measured by ELISA assay. (B) MDA-MB-231 and MCF-7 cells with ADCY4 ectopic expression or control cells were treated with vehicle (DMSO) or SC79, cAMP concentration was measured the same as in (A). (C) MDA-MB-231 and MCF-7 cells with ADCY4 ectopic expression or control cells were treated with vehicle (DMSO) or tBHQ, cAMP concentration was measured the same as in (A). (D) MDA-MB-231 and MCF-7 cells with ADCY4 ectopic expression or control cells were treated the same as in (A), the cell viabilities were measured by MTT assay at 24, 48, 72, and 96 h. (E) MDA-MB-231 and MCF-7 cells with ADCY4 ectopic expression or control cells were treated the same as in A), the percentages of apoptotic cells were measured. (F) Proposed model of alternative mechanism of conversing ATP to cAMP and suppression of downstream FAK/AKT and ERK signaling via ADCY4 during breast carcinogenesis. Loss of ADCY4 is detected in BC and tightly correlated with promoter CpG methylation. ADCY4 restoration inhibits breast carcinoma cell growth and metablism through cAMP/PKA and its downstream FAK/AKT and ERK signaling pathways. ***p < 0.001, **p < 0.01, *p < 0.05.
Fig. 6 cAMP plays an important role in ADCY4-regulated signaling pathways. (A) MDA-MB-231 and MCF-7 cells with ADCY4 ectopic expression or control cells were treated with vehicle (DMSO) or SQ22536, cAMP concentration was measured by ELISA assay. (B) MDA-MB-231 and MCF-7 cells with ADCY4 ectopic expression or control cells were treated with vehicle (DMSO) or SC79, cAMP concentration was measured the same as in (A). (C) MDA-MB-231 and MCF-7 cells with ADCY4 ectopic expression or control cells were treated with vehicle (DMSO) or tBHQ, cAMP concentration was measured the same as in (A). (D) MDA-MB-231 and MCF-7 cells with ADCY4 ectopic expression or control cells were treated the same as in (A), the cell viabilities were measured by MTT assay at 24, 48, 72, and 96 h. (E) MDA-MB-231 and MCF-7 cells with ADCY4 ectopic expression or control cells were treated the same as in A), the percentages of apoptotic cells were measured. (F) Proposed model of alternative mechanism of conversing ATP to cAMP and suppression of downstream FAK/AKT and ERK signaling via ADCY4 during breast carcinogenesis. Loss of ADCY4 is detected in BC and tightly correlated with promoter CpG methylation. ADCY4 restoration inhibits breast carcinoma cell growth and metablism through cAMP/PKA and its downstream FAK/AKT and ERK signaling pathways. ***p < 0.001, **p < 0.01, *p < 0.05.CC BY-NC-ND · PubMed Central
Fig. 7 ADCY4 sensitized the respond of BC cells to paclitaxel. (A–C) Viability rate of proliferation in ADCY4 ectopic expression or control BC cells (MDA-MB-231, MCF-7, and SK-BR-3) treated with gradient concentration of Paclitaxel. (D) IC50 values of paclitaxel for BC cells.
Fig. 7 ADCY4 sensitized the respond of BC cells to paclitaxel. (A–C) Viability rate of proliferation in ADCY4 ectopic expression or control BC cells (MDA-MB-231, MCF-7, and SK-BR-3) treated with gradient concentration of Paclitaxel. (D) IC50 values of paclitaxel for BC cells.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 62 references

Cited by

See all 4

Metadata

Authors
Pan, G., Huang, M., Fu, S., Wang, Y., He, L., Wu, B., Yang, J., Lin, S., & Fan, Y.
Affiliations
  • Southwest Medical University (CN)
  • The First People's Hospital of Guangyuan (CN)
Corresponding author
Pan, Guangrui
Venue
Scientific Reports
Published
2025-07-01
Volume
15
Issue
1
Pages
20426-20426
ISSN
2045-2322 (ISSN-L)
OpenAlex
W4411885734
Cited by
3
References
62
Citations by year
2026: 2 · 2025: 1
FWCI
0.90
Type
journal article
Language
en
Open access
Licence
Locations
  • Scientific Reports (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Wu Jieping Medical Foundation (320.6750.2023-18-100)
  • Sichuan Provincial Science and Technology Support Program (2022NSFSC1425)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mechanisms of cancer metastasis
Keywords
breast cancer, DNA methylation, epigenetic silencing, cAMP signaling, protein kinase A, FAK/AKT signaling, ERK signaling, tumor suppressor, cell proliferation, apoptosis, metastasis, hypomethylating agents, histone deacetylase inhibitors
MeSH terms
Cyclic AMP, Adenylyl Cyclases, Animals, Breast Neoplasms, Female, Humans, Signal Transduction, Gene Expression Regulation, Neoplastic, Apoptosis, DNA Methylation, Gene Silencing, MAP Kinase Signaling System, Cell Line, Tumor, Cell Proliferation, Proto-Oncogene Proteins c-akt, Focal Adhesion Kinase 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: ADCY4 inhibits cAMP-induced growth of breast cancer by inactivating FAK/AKT and ERK signaling but is frequently silenced by DNA methylation. https://app.cochat.ai/papers/10.1038/s41598-025-06294-1
The paper
Pan, G., Huang, M., Fu, S., Wang, Y., He, L., Wu, B., Yang, J., Lin, S., & Fan, Y. (2025). ADCY4 inhibits cAMP-induced growth of breast cancer by inactivating FAK/AKT and ERK signaling but is frequently silenced by DNA methylation. Scientific Reports. https://doi.org/10.1038/s41598-025-06294-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.